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Despite high reported coverage for routine and supple-
mentary immunization, in 2010 in Malawi, a large measles 
outbreak occurred that comprised 134,000 cases and 304 
deaths. Although the highest attack rates were for young 
children (2.3%, 7.6%, and 4.5% for children <6, 6–8, and 
9–11 months, respectively), persons >15 years of age were 
highly affected (1.0% and 0.4% for persons 15–19 and >19 
years, respectively; 28% of all cases). A survey in 8 dis-
tricts showed routine coverage of 95.0% for children 12–23 
months; 57.9% for children 9–11 months; and 60.7% for 
children covered during the last supplementary immuniza-
tion activities in 2008. Vaccine effectiveness was 83.9% for 
1 dose and 90.5% for 2 doses. A continuous accumulation 
of susceptible persons during the past decade probably 
accounts for this outbreak. Countries en route to measles 
elimination, such as Malawi, should improve outbreak 
preparedness. Timeliness and the population chosen are 
crucial elements for reactive campaigns.
During the prevaccine era, 130 million measles cases occurred annually worldwide, and measles was a 
leading cause of childhood death (1). Measles vaccines 
have dramatically reduced cases and deaths during recent 
decades. The Measles Initiative developed a joint strategic 
plan to reduce measles-related deaths by strengthening 
routine immunization, supplementary immunization 
activities (SIAs) in the form of mass vaccination 
campaigns, reinforced surveillance, and adequate case 
management (2,3). In 2000, the World Health Organization 
(WHO) Regional Office for Africa adopted a plan to reduce 
measles-related deaths by 50% by the end of 2005 (3,4), 
and measles-related deaths decreased from 535,300 in 2000 
to 139,300 in 2010 (5). A recent WHO resolution called for 
measles elimination in the African Region by 2020 (6).
Malawi’s Expanded Program on Immunization (EPI), 
established in 1979, recommends 1 dose of measles-
containing vaccine (MCV) for infants 9–11 months of 
age (7). After implementation of EPI, cases declined from 
>162,000 in 1980 to an annual average of 8,000 cases 
throughout the 1990s. Additional initiatives toward measles 
control (8) comprised a catch-up campaign in 1998 directed 
toward children 9 months–14 years of age and follow-
up campaigns in 2002, 2005, and 2008 for children 9–59 
months (9); administrative reported vaccine coverage was 
close to 100% (10). Before 2010, the last large epidemic in 
Malawi occurred in 1996 and 1997, when ≈10,000 cases 
were reported nationwide each year.
Despite Malawi’s measles control successes during the 
past 2 decades, a large outbreak occurred in 2010, with as 
many cases as in the 1980s. Médecins Sans Frontières (MSF) 
with the Ministry of Health (MoH) reinforced surveillance, 
provided case management, and vaccinated 3,343,112 
children through outbreak response immunization (MoH/
MSF) during epidemiologic weeks 18–26 (May–June) 
(Figure 1, panel A). The MoH implemented additional 
reactive vaccination campaigns for 1) children 9–59 
months of age in some districts in epidemiologic weeks 
10–14 (March–April) and 2) children 9 months–15 years 
of age nationwide in epidemiologic weeks 33–34 (August).
To describe this epidemic and outcomes from outbreak 
response vaccination, we analyzed national surveillance 
data. We also addressed factors that might explain the 
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National surveillance in Malawi is based on the 
Integrated Disease Surveillance and Response strategy. 
Each month, health officers from public health facilities 
and selected private centers report cases and deaths to 
the district level. Data are electronically compiled and 
transmitted monthly to the national level. A standardized 
individual collection form is used to collect information 
about age, sex, health facility, date of consultation, date 
of onset, whether specimen was sent to the laboratory, 
treatment, and outcome (alive or dead).
Health care providers used WHO case definitions to 
diagnose measles cases and to report case-patients in the 
surveillance system. Suspected measles was defined as 
generalized maculopapular rash and fever (>38°C) and at 
least 1 of the following: cough, runny nose, or conjunctivitis; 
or as suspected measles reported by a health professional. A 
measles-related death was defined as the death of a person 
with measles within 30 days after rash onset, unless the 
death was unrelated to the disease. Samples from suspected 
case-patients were sent for laboratory confirmation to detect 
measles IgM. Three confirmed cases at the district level 
constituted an outbreak. Once an outbreak was confirmed, 
additional cases were confirmed by epidemiologic link if 
they met the clinical case definition (1).
During the 2010 outbreak, the surveillance system was 
strengthened by reinforcing health officer training (case 
definition and data collection), retrospective review of 
health registers, weekly communication to the district level 
for data sharing, monitoring of data completeness, and 
electronic compilation and cleaning of the line list. Data 
collection strengthening was interrupted in epidemiologic 
week 35 when MSF involvement in measles case 
management ended.
Data were entered in Excel (Microsoft, Redmond, 
WA, USA). Attack rates (ARs) were defined as the number 
of measles cases divided by the population at risk and 
case-fatality rates (CFRs) as the number of measles-related 
deaths divided by the number of measles cases. Population 
projections for 2010 were calculated by applying a growth 
rate of 3.28% to the 2008 Malawi Population and Housing 
Census figures.
Vaccine Coverage and Effectiveness
We conducted age-stratified surveys (epidemiologic 
weeks 27–31 [July–August 2010]) to assess coverage 
in the districts where MoH/MSF conducted vaccination 
campaigns (Figure 1, panel B). Children 6 months–15 
years of age were eligible for inclusion in the surveys. For 
each district, we required a sample of 983 on the basis of 
the following assumptions: 80% vaccine coverage, an α 
error of 0.05, an absolute precision of 0.05, and a design 
effect of 4.
We used cluster sampling (40 villages of 25 children in 
each district); clusters were allocated proportionately to the 
Figure 1. Weekly distribution of measles cases and time when the reactive vaccination campaigns were implemented (A) and districts 
where outbreak-response immunizations were conducted by the MoH and MSF (B), Malawi, 2010. MoH, Ministry of Health; MSF, 
Médecins Sans Frontières; BLT, Blantyre; MZB, Mzimba, LLW, Lilongwe; THY, Thyolo; CDZ, Chiradzulu; MGC, Mangochi; BLK, Balaka; 
MCG, Machinga. Black arrows indicate compaigns implemented by MoH/MSF; gray arrows indicate campaigns implemented by MoH only.
204 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 19, No. 2, February 2013
population of each village or health center catchment area 
where village populations were not available. In the urban 
areas of Blantyre and Lilongwe, spatial-based sampling 
was used to select randomly the first household of clusters 
(11). In rural areas, the households in the villages were 
numbered, and the first household was randomly selected. 
Subsequent households were selected by proximity. 
Households were defined as persons living and eating 
together under the same roof. If a head of household or 
adult was absent, the survey team returned later in the day; 
if a head of household was absent after 2 attempts, the 
household was skipped and replaced.
A standardized questionnaire was used to collect 
demographic data, vaccination status, and vaccination 
history (place, date of vaccination, and injection site on 
the body) for routine vaccination, last SIAs (October 2008) 
and MoH/MSF campaigns (May–July 2010), reasons for 
nonvaccination for routine vaccination and MoH/MSF 
outbreak response immunization, and previous measles 
episodes. Proof of vaccination status was verified in the 
health passport; otherwise we relied on verbal recall. We 
also asked for respondents’ age and degree of literacy.
To estimate vaccine effectiveness, we identified all 
children born after October 2003 (oldest age group toward 
which the 2008 follow-up SIAs were directed) with known 
vaccination status and no previous measles episode before 
2010 among those recruited for the vaccine coverage survey. 
The main exposure of interest was vaccination status. 
Children were classified as not vaccinated, vaccinated with the 
routine dose only (routine vaccination ascertained by health 
passport), or vaccinated with 2 doses (routine vaccination 
ascertained by health passport plus the 2008 SIAs). Case-
patients were defined as any child 9 months–15 years of age 
whose illness met the WHO measles case definition from 
January 2010 to the date of MoH/MSF outbreak response 
immunization in the different districts. Additional variables 
considered as possible confounders were age and literacy of 
the main caregiver and district of residence.
Vaccination coverage estimates were obtained by 
taking into account the survey design; sampling weights 
and design effect (deff) were applied to obtain the estimates 
(12). Associations between vaccination status and outcome 
were assessed through binomial regression (log link). The 
exponential of the coefficient for the vaccination variable 
was computed to estimate the adjusted risk ratio, and p 
values <0.05 were regarded as significant. The adjusted 
level of vaccine protection was computed as follows: (1 
- adjusted risk ratio) × 100. Confidence intervals were 
calculated by taking into account the deff.
Data were entered by using EpiData 3.1 (EpiData 
Association, Odense, Denmark). Data analysis was 
performed by using Stata 10.0 (Stata Corp., College 
Station, TX, USA).
Ethical Considerations
The study was implemented in collaboration with the 
MoH after obtaining authorization. Privacy, confidentiality, 
and rights of patients were ensured during and after the 
study. Verbal informed consent was obtained from each 
head of household visited after detailed explanation about 
the existence of the outbreak, study objective, and planned 
use of the data collected. The survey data were entered and 
analyzed anonymously.
Main Findings
Description of the Outbreak
In January 2010, sporadic suspected measles cases 
were reported in Blantyre and Zomba districts (Southern 
Region) and in Mzimba and Nkhata Bay districts (Northern 
Region). The first samples were confirmed measles IgM 
positive on week 3. For the first few weeks, most reported 
cases were from the urban area of Blantyre, but by the end 
of March, all 3 regions were affected; the bulk of cases 
came from a few districts: Blantyre, Chiradzulu, Mangochi, 
Machinga, Zomba, and Thyolo (Southern Region); Mzimba 
(Northern Region); and Lilongwe (Central Region). By 
mid-July, all districts reported measles cases.
During weeks 1–52, a total of 134,039 measles cases 
and 304 deaths were reported. At the national level, the 
epidemic plateaued on week 23, and reported cases started 
to decrease in week 32 (Figure 1). The overall cumulative 
AR was 0.96%. The CFR was 0.23%.
The most affected areas were the Central Region and 
the Southern Region, where cumulative ARs were 1.09% 
and 1.03%, respectively; in the Northern Region, the 
AR was 0.28%. In the Southern Region, cases peaked in 
week 23, and in the Central Region, in week 32 (Figure 2).
Measles cases were equally distributed between male 
and female patients (M:F ratio 1.03:1) (Table 1). Median 
age of case-patients was 7 years (interquartile range 1–16). 
A total of 54,138 case-patients were <5 years of age, 
constituting 42% of all cases; 30% of case-patients were 
5–14 years old, and 28% were adults (>15 years). The most 
affected age groups were infants <1 year of age; AR was 
highest among children 6–8 months of age, followed by 
those 9–11 months (Figure 3).
Vaccine Coverage and Effectiveness
A total of 9,381 households were visited, and 21,993 
children participated in the surveys. The median age of 
children was 6.8 years (interquartile range 3–10 years).
In the 8 districts surveyed, 95.0% (95% CI 93.7%–
96.0%, deff 1.5) of children 12–23 months of age were 
vaccinated through EPI (Figure 4). A similar percentage 
(96.9% [95% CI 96.4%–97.3%, deff 4.0] ), was observed 
overall. Reason for nonvaccination was obtained for 661 
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(88.6%) children not vaccinated through EPI. Caregivers 
decided not to vaccinate the child in 61.8% of instances; 
the rest were unable to vaccinate the child despite their 
willingness because of reasons such as distance and cost. 
The main reason for nonvaccination was the caregiver’s 
belief that the child was too young (36.0%); few (4.4%) 
declared religious objection to vaccination.
As reported by the caregiver, 60.8% (95% CI 58.3%–
63.1%, deff 5.7) of children 9 months–5 years of age at the 
time of the SIA in 2008 were vaccinated against measles 
during this SIA; 0.7% of these children received the first 
dose, 60.1% received the second dose, and 39.2% were not 
vaccinated. Children not included in the age group toward 
which immunization was directed were vaccinated during 
the SIA (11% of children 0–9 months and 19% of children 
5–10 years). Among the 159 (1.7%) children 9 months–5 
years of age not vaccinated through EPI by October 2008, 
54 (34.8%) were vaccinated in the SIA.
Coverage of the MoH/MSF outbreak response 
immunization was 95.5% (95% CI 94.9%–96.1%, deff 4.7) 
and lowest in children 6 months–1 year of age (Figure 
4). Results were similar across the 8 districts surveyed 
(Table 2).
In total, 175 (3.4%) children among the 5,082 in the 
effectiveness survey reported a measles episode in 2010 
before the MoH/MSF outbreak response immunization 
was implemented. Most (90.8%) children consulted in a 
health facility, and 21.8% were hospitalized. The vaccine 
effectiveness adjusted by child’s age, sex, and location and 
the main caregiver’s literacy was 83.9% (95% CI 70.8%–
90.8%) for 1 EPI dose and 90.5% (95% CI 79.7%–95.5%) 
for 2 doses (EPI and SIAs) (Table 3). Vaccine effectiveness 
was highest among children 1–2 years, but effectiveness 
did not significantly differ by age group (data not shown).
Lessons Learned
In November 2009, WHO and the Global Alliance on 
Vaccination and Immunization rewarded the Malawi MoH 
for its outstanding performance in improving child health 
and immunization. The measles control program in Malawi 
is, to a large extent, a success story. However, despite high 
reported coverage for both EPI and SIAs, implemented in 
Figure 2. Measles cumulative attack rates (ARs) by district and weekly incidence, in Malawi, 2010. A) Malawi. The white area is Malawi 
Lake. Asterisks indicate districts in which children were vaccinated. B) Northern Region. C) Southern Region. D) Central Region. 
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recent years in a timely manner, in 2010 Malawi faced its 
largest measles outbreak in >2 decades, with a number of 
reported cases comparable to the prevaccine era.
Malawi reported fewer deaths from measles than did 
other African countries where measles outbreaks recently 
occurred (13–15). Although measles-related deaths are 
known to be underreported, perhaps the best explanation for 
low numbers of reported deaths is the high measles vaccine 
coverage combined with the lower CFR among vaccinated 
case-patients (16,17). In addition, a high proportion of 
cases occurred in older children and young adults, who are 
at lower risk for death (18–20). The wide age distribution 
documented in this outbreak corresponds to a setting with 
good coverage and adequate vaccine effectiveness but 
insufficient to achieve elimination (18).
The EPI measles coverage (first dose of MCV) was 
high according to administrative estimates and from the 
results of vaccine coverage surveys in selected districts. 
Nonetheless, children 9–11 months of age were one of 
the most affected age groups during the 2010 outbreak. 
The routine vaccine coverage was low for this group, 
suggesting that children are vaccinated toward the end of or 
after the recommended period for EPI. The main reason for 
nonvaccination was the belief that the child was too young 
to be vaccinated. This issue highlights the need to reinforce 
routine vaccination, even in high-performing programs 
such as that in Malawi, and to include clear advice on the 
age for vaccination (19). In Malawi, the first measles dose 
is recommended at 9–11 months; however, older children 
also should be vaccinated through the routine program if 
they have not been vaccinated at the recommended age.
ARs during the 2010 outbreak were highest for age 
groups not yet vaccinated or for children who had received 
only 1 dose of MCV (i.e., children born after the last SIAs in 
October 2008). However, ARs also were relatively high for 
age groups eligible for SIAs. The reported administrative 
coverage of the last SIA in 2008 was 98% (10), but survey 
results indicate that only 61% of children eligible for the 
SIA in 2008 were vaccinated. The discrepancy between 
survey figures and the administrative coverage might 
Table 1. Characteristics of persons reported to have measles, Malawi, 2010 
Characteristic No. (%) cases reported Attack rate* No. (%) deaths reported Case-fatality rate† 
Total Malawi 134,039 (100) 0.96 304 (100) 0.23 
 Northern Region 5,054 (4) 0.28 24 (8) 0.47 
 Central Region 64,688 (48) 1.09 152 (50) 0.23 
 Southern Region 64,297 (48) 1.03 128 (42) 0.20 
Sex 133,834 (100)  304 (100)  
 M 67,949 (51) 0.97 126 (41) 0.19 
 F 65,885 (49) 0.94 178 (59) 0.27 
Age group 131,725 (100)  292 (100)  
 0–5 mo 7,243 (6) 2.26 10 (3) 0.14 
 6–8 mo 10,615 (8) 7.61 27 (9) 0.25 
 9–11 mo 7,543 (6) 4.5 21 (7) 0.28 
 12–59 mo 28,737 (22) 1.38 81 (28) 0.28 
 5–14 y 39,979 (30) 1.02 69 (24) 0.17 
 15–19 y 13,641 (10) 1.0 14 (5) 0.10 
 >20 y 23,967 (18) 0.4 70 (24) 0.29 
*Per 100 persons.  
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be explained by denominator problems (administrative 
coverage), by possible recall bias (survey coverage), and 
by the fact that children out of the age groups toward which 
routine vaccination is directed are vaccinated during the 
SIA as documented in our survey. Most children vaccinated 
during the SIA already had been vaccinated through EPI; 
the SIA captured only one third of those not yet vaccinated.
We estimated the vaccine effectiveness for 1 dose 
to be 84%, meaning that each year 16% of children 
vaccinated through the routine program in Malawi are not 
protected. This percentage is expected for a vaccination that 
recommends giving a first dose to children at 9 months of age 
(the seroconversion rate at this age is 85%–90%) (20) but is 
insufficient to prevent measles outbreaks, as was shown in 
Malawi. One option for increasing vaccine effectiveness 
is to provide the first measles dose at 12 months, when 
seroconversion is more likely (21). WHO recommends this 
strategy in the absence of large outbreaks and documented 
good coverage. Nonetheless, when this schedule is followed, 
the children remain susceptible to measles infection for an 
additional 3 months, and in countries with a high birth rate 
(such as Malawi), this schedule may result in the buildup of 
a large cohort of susceptible children. Because the youngest 
children are at higher risk for measles-related death (17), 
careful consideration must be given to any increase in the 
age at first measles vaccination, especially if the risk for an 
outbreak remains high (22).
Reaching all children with 2 doses of MCV should 
be the standard for all national immunization programs—
especially in countries with an elimination goal—to increase 
the seroconversion rates (20). However, in our study the 
estimated effectiveness of the second dose was lower than 
expected; for children receiving the second measles vaccine 
dose through the 2008 SIA, vaccine effectiveness was 91%. 
Factors that can reduce vaccine protection include failure in 
the cold chain, interaction with maternal antibodies, waning 
immunity, and the HIV pandemic (23). The vaccine is less 
effective in HIV-infected children because of quick loss of 
protective antibodies after immunization (24). In Malawi, 
≈1%–2% of children <15 years of age are HIV infected (25). 
WHO recommends vaccination at 6 months in addition to 
the normal schedule in areas with high HIV prevalence and 
measles transmission (20), and incorporating this guidance 
into the routine program remains a priority.
Despite several reactive vaccination campaigns, the 
epidemic spread throughout Malawi. WHO guidelines on 
measles outbreak response suggest that reactive vaccination 
should be implemented as quickly as possible; at-risk groups 
and affected areas also should be considered as areas that are 
not yet affected but have high epidemic risk (1). The MoH 
campaign conducted early during the outbreak (March–
April) was not wide enough in terms of focus population and 
geographic extension to contain the epidemic. The MoH/
MSF nonselective campaigns were implemented in several 
districts for children 6 months–15 years of age, but more 
than one third of cases were reported among older persons. 
Despite overall high vaccine coverage obtained without 
major differences across districts, most of these campaigns 
were implemented late in the epidemic (during or after the 
peak) (online Technical Appendix Figure, wwwnc.cdc.gov/
EID/article12-0301-Techapp1.pdf). In addition, campaigns 
were conducted in some of the most affected districts but not 
in neighboring districts with high transmission. The national 
mass vaccination campaign conducted by the MoH in 
August (reported administrative vaccine coverage of 107%) 
also was implemented late in the course of the epidemic and 
also focused on persons <15 years of age. The timeliness of 
the intervention is probably the major factor determining the 
effect of the outbreak response; the delay in Malawi probably 
decreased the effect of the immunization campaigns. Our 
experience in 2010 shows that better preparedness plans for 
outbreak response are needed to improve the timeliness of 
Figure 4. Measles vaccine coverage for the Expanded Program 
on Immunization and outbreak-response immunization conducted 
by the Ministry of Health and Médecins Sans Frontières in 
8 districts (Blantyre, Mzimba, Lilongwe, Thyolo, Chiradzulu, 
Mangochi, Balaka, and Machinga), Malawi, 2010. *EPI; †ORI; 
black bars, vaccination ascertained by health passport; gray bars, 
EPI vaccination ascertianed by oral reporting; white bars, ORI 
vaccination ascertained by oral reporting.
Table 2. Measles vaccination coverage estimates in 8 districts, Malawi, 2010* 
Vaccination coverage, age group 
Estimates, % (95% CI) 
Blantyre Chiradzulu Lilongwe Mzimba Thyolo Mangochi Bal-Mach 
Routine EPI vaccination, 9 mo–15 y 98 (96–98) 99 (98–99) 95 (92–97) 95 (93–97) 97 (96–98) 96 (95–97) 98 (97–99) 
MoH/MSF reactive campaign, 6 mo–15 y 93 (91–94) 98 (97–98) 96 (94–97) 92 (90–94) 97 (95–97) 96 (95–98) 96 (94–97) 
SIA October 2008, 9 mo–5 y 47 (40–54) 57 (52–63) 60 (55–65) 47 (41–53) 69 (64–74) 63 (57–68) 6 (63–74) 
*Bal-Mach, Balaka-Machinga; EPI, Expanded Program on Immunization; MoH/MSF, Ministry of Health/ Médecins Sans Frontières; SIA, supplementary 
immunization activity. 
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such interventions. Prior evidence favored conducting timely 
reactive campaigns directed toward children 6 months–15 
years to maximize cases averted (26). However, in areas 
such as Malawi, where older age groups are highly affected, 
efforts directed toward persons >15 years of age would have 
had a greater effect on the transmission dynamics.
Our field studies have some key limitations. First, 
despite the effort to detect and report all suspected 
measles cases and related deaths to the national 
surveillance system, only case-patients seeking treatment 
at health facilities were recorded. Thus, the actual number 
of measles cases and measles-related deaths remain 
unknown. In addition, completeness of case reporting and 
sensitivity of the surveillance system were not assessed. 
However, health services are accessible and functional 
in Malawi, and free treatment for measles was provided 
during the epidemic; moreover the survey results showed 
that most of the children were vaccinated at a health 
facility. Despite the effort to standardize procedures for 
data collection in all districts, active surveillance was 
reinforced more in districts where case management 
was implemented by MSF. Thus, differences in number 
of cases reported might partially reflect the difference in 
performance of the surveillance system.
Second, we conducted surveys only in districts where 
reactive vaccination campaigns were implemented, which 
makes extrapolation to the country difficult. In addition, 
because not all children had health passports, vaccination 
coverage was assessed by parental recall, leading to 
possible overestimation or underestimation of coverage. To 
minimize misclassification of verbally reported vaccination 
status, we asked parents to name the vaccination place and 
the part of the body where the vaccine was delivered (e.g., 
shoulder, leg, other) to determine whether the caregiver 
correctly remembered a vaccine consistent with measles 
vaccine delivery. Previous studies in areas of high measles 
incidence have shown parental recall to be reliable (27). 
We suspect underreporting for the 2008 SIA given that all 
the information for this estimate was collected from verbal 
reporting because documentation was not available and the 
recall period was long.
Third, misclassification of SIA vaccination status might 
have decreased the vaccine effectiveness estimate for the 
second dose (28) and should be considered as an additional 
reason to explain the lower-than-expected vaccine 
effectiveness for 2 doses. Regarding the retrospective 
ascertainment of measles cases, we used the local term for 
measles to increase the sensitivity and specificity of the case 
definition (29). However, if misclassification is present, it 
probably does not differ for vaccinated and nonvaccinated 
children. Finally, we did not collect information about 
measles-related deaths, which might slightly downward 
bias our estimate of vaccine efficacy.
Measles and measles-related deaths have decreased 
dramatically during recent decades in Malawi thanks to 
a comprehensive measles control strategy. However, our 
results highlight the difficulties in avoiding large outbreaks, 
even with successful routine programs. Control programs 
need to be adapted to the epidemiologic context, including age 
range for routine vaccination. SIAs are crucial for reducing 
the number of susceptible children. This SIA strategy has 
been successfully implemented in the Americas, which 
achieved measles elimination in 2003, but reality shows the 
complexity of obtaining similar outcomes in other locations. 
SIAs could focus on a wider age range if older nonvaccinated 
persons are expected. We also highlight the need for the 
timeliness and choice of the population outbreak response 
immunizations. Age groups toward which vaccination efforts 
are directed should be determined according to local measles 
epidemiology. To provide timely and adequate responses 
in similar contexts, better preparedness plans for possible 
outbreaks based on proper risk assessments, including good 
estimates of vaccine coverage, are urgently needed.
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